Metatron Inc (MRNJ): MRNJ>>>11/13/2024 MRNJ OTCMarkets...

yadotn · 2024-11-15T02:06:30.6500000Z

MRNJ>>>11/13/2024 MRNJ OTCMarkets November 13, 2024 Authorized Shares 24,000,000,000 Outstanding Shares 15,245,183,242 https://www.otcmarkets.com/stock/MRNJ/security

Play Episode

3min

Proactive - Interviews for investors

Delivra Health expands Dream Water line with 6-count sleep gummies in Canada

Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to announce the launch of Dream Water 6-Count Sleep Gummies in the Canadian market. This new product builds on the success of the 60-count Dream Water Gummies, which debuted in Canada in February 2024 and received strong consumer demand. The 6-count version is set to hit distributors, retailers, and e-commerce channels in March 2025. Davey highlighted that this strategic launch is aimed at capturing growth opportunities in the travel and convenience retail sectors, reinforcing Delivra Health’s position as a leading provider of sleep solutions. By offering a smaller, on-the-go format, the company aims to expand its reach to travelers and impulse buyers, broadening accessibility for consumers seeking convenient sleep aids. The momentum behind Dream Water Sleep Gummies continues to build in both Canada and the U.S., with the new 6-count format being distributed nationwide through Delivra Health’s established retail and e-commerce partners. With this expansion, the company is set to further strengthen its footprint in the sleep wellness market. #proactiveinveestors #delivrahealthbrandsinc #tsxv #dhb #otcqb #dhbuf #DreamWater #GlobalExpansion #UAE #MiddleEastMarket #SleepAid #HealthAndWellness #PharmacyProducts #RegulatoryCompliance #DreamWater #SleepGummies #Wellness #SleepAid #TravelEssentials #CanadianRetail #HealthAndWellness #InsomniaRelief #SleepBetter

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Proactive - Interviews for investors

Provaris Energy in 'sweet spot' with second MOU for hydrogen transport

Provaris Energy Ltd (ASX:PV1, OTC:GBBLF) managing director and CEO Martin Carolan talked with Proactive about the company’s latest progress in hydrogen transport and storage solutions. The company has signed a second non-binding memorandum of understanding (MoU) to supply hydrogen from Norway to Germany, aiming for discussions on non-binding term sheets by mid-2025. Carolan emphasised that Provaris is in a "sweet spot" given the industry’s shift towards practical hydrogen projects, with a focus on cost efficiency and scalable delivery. He highlighted that recent developments in Germany reinforce the country’s commitment to hydrogen as a decarbonistion strategy. Additionally, Provaris is advancing its CO2 storage initiative through a joint development with Yinson Production, targeting large-scale liquid CO2 storage solutions. The company also secured the Fiska facility in Norway, which will play a role in testing and validating its H2 Neo carrier technology. Looking ahead, Carolan noted that investors can anticipate key milestones, including binding hydrogen sales agreements and further progress on CO2 storage projects. For more insights from industry leaders, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications for future updates. #ProvarisEnergy #Hydrogen #EnergyTransition #Germany #Norway #CO2Storage #RenewableEnergy #SustainableSolutions #HydrogenTransport #GreenEnergy

Proactive - Interviews for investors

North Bay Resources reports high-grade copper results from Feb 2025 exploration at Copper Island

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to unveil the latest exploration results from the company’s Copper Island Project, following a comprehensive rock sampling program conducted in February 2025. The program targeted eight outcrops within the Pomeroy 1-3, Beaver, and Copper Bell zones, yielding highly promising results. According to Lazerson, assay results revealed copper concentrations as high as 5.69%, along with silver reaching 1 ounce per ton and vanadium at 0.22%. The average assay values stood at 4.6% copper, 0.5 ounces per ton silver, and 0.9% vanadium, further underscoring the project’s potential. Additionally, metallurgical testing indicated that copper mineralization exists in oxide form up to 74.4%, with average oxide copper content of 40.3%, 42.1%, and 58.4% across three different leach tests. This is a crucial finding, as copper in oxide form is typically associated with lower processing costs and higher recovery rates, enhancing the project's economic viability. The Pomeroy 3-4 Zone, one of the most significant areas of interest, exhibits mineralization over a strike length of approximately 750 feet—making it the largest of the numerous copper-silver zones identified to date. The mineralization is associated with a northwest-to-north-trending sequence of amygdaloidal basaltic flows, with key east-west to east-northeast-south-southwest cross-cutting fault and fracture zones contributing to the structural complexity. Multiple parallel mineralized zones have also been identified, further expanding the project's exploration potential. With these encouraging results, North Bay Resources continues to advance its exploration efforts, positioning the Copper Island Project as a compelling opportunity in the copper and critical minerals sector. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #

Followers	4
Posts	1343
Boards Moderated	0
Alias Born	12/28/2016

Volume:	1,615,447
Day Range:	0.0001 - 0.0001
Bid:	0.0001
Ask:	0.0001
Last Trade Time:	10:00:04 AM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MRNJ Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free